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The negative association between inflammatory bowel 
disease and Helicobacter pylori seropositivity 
 
Abstract 
Background: The role of Helicobacter pylori (H. pylori) in inflammatory bowel disease is 
a controversial argument. The initial theory of this study was that Helicobacter is a risk 
factor for inflammatory bowel disease. In this study, we investigated the coincidence of H. 
pylori exposure and IBDs. 
Methods: This case-control study has been done in Babol, teaching Hospitals; 60 newly 
diagnosed IBD cases without any Helicobacter eradicating treatment and 120 control 
patients without inflammatory bowel disease evidence in biopsy, investigated for H. pylori 
exposure by IgA and IgG ELISA tests. Clinical information, demographics and ELISA test 
results have been analyzed using SPSS.Version.18 (level of significance was less than 
0.05). 
Results: Mean age of case group was 42.27±13.64 years; in control group it was 
45.52±13.83 years. There was a significant difference between the case and control groups 
in IgG study of the following subgroups: age under 30, females, males, urban, higher 
education level and BMI between 18.5 and 24.9 (p-value was respectively; 0.004, 0.014, 
0.047, 0.002, 0.013, 0.003). On the basis of logistic regression; IBD was less common in 
females, patients with lower education and patients with positive result of IgG (p-value 
was respectively 0.002, 0.013, 0.010). 
Conclusion: As a result of this study, Helicobacter pylori exposure, may could play a 
protective role against inflammatory bowel disease. 
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Glassified as Crohn’s disease and ulcerative colitis, IBDs have a recurrent-quiescent 
nature. They can cause tissue damage, surgical interventions, and failure or functional 
disabilities of the digestive system over the course of time. It is assumed that IBDs result 
from a complicated and unknown confrontation between environmental factors (such as 
infections, drugs, tobacco, food particles) and genetic factors of a host (1-4). Several 
studies have been conducted on its role in other conditions for example colon cancer. 
Helicobacter pylori plays a protective role against some autoimmune diseases such as 
asthma and diabetes mellitus type 1. The mechanism of this protective role is still 
unknown. However, it appears that a distinct expression of an acute or chronic immune 
response to topical mucosal inflammation affects it. This response releases cytokines 
systematically. On the contrary, it can regulate the systematic immune response and 
suppress self-immunity by banishing the response from Th1/Th17 (1, 2, 5). Derangement 
of host immune response to common bacteria is known as an important pathogenic 
mechanism in IBD.  
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An increase has been observed in intestinal bacteria 
connected to intestinal epithelium in IBDs. This theory 
increases the probability that H. pylori can play a role in 
IBDs; On the other hand, H. pylori is seen more in 
communities with lower socioeconomic status. It becomes 
less prevalent by improving hygiene. However, IBD is 
observed more common in population with higher 
socioeconomic levels (6). Therefore, it appears that there 
must be an inverse relationship between the prevalence of 
helicobacter pylori and IBD (1, 2, 7-9). Moreover, a 
continuous increase has been reported in the emergence of 
ulcerative colitis in areas with endemic H. pylori and where 
helicobacter has been eradicated (2).  
In 2017, 41 studies were assessed and results showed the 
incidence and prevalence of Crohn’s disease that was 
inversely and significantly associated with prevalence of H. 
pylori infection. The studies were conducted in Europe, 
Japan, USA and Australia (10). The presence of specific 
antibodies of IgA and IgG classes in the serum against 
bacteria is a diagnostic factor of bacterial exposure and 
ELISA is a selective technique for diagnosing these 
antibodies (11). The aim of this study was to investigate the 
coincidence of H. pylori exposure in patients with active 
destructive colitis and in control group visiting endoscopy 
wards of teaching hospitals in Babol, Iran in 2015-2016. The 
socioeconomic factors were also included to assess 
association dependency to these factors due to insufficiency 
of data in this context. 
 
 
Methods 
This case-control study was conducted on patients with 
the symptoms of IBDs (like abdominal pain, rectal bleeding 
and weight loss) visiting the endoscopy wards of teaching 
hospitals in Babol, Iran from March 20, 2015 to March 20, 
2016 using the simple random sampling method. The 
patients were asked for written consent. Ethical approval for 
this study was obtained from the Ethics Committee of Babol 
University of Medical Sciences 
(MUBABOL.REC.1394.214). with presumption of 50% H. 
pylori seropositivity, there were 180 samples selected in total 
to identify the effect of 20% in H. pylori seropositivity at a 
95% confidence level and 80% statistical power between the 
cases and control groups. Sixty cases were selected with new 
diagnosis of IBD (ulcerative colitis or Crohn’s disease) 
according to the evidence of IBD in both colonoscopy and 
pathology report of biopsy. A hundred twenty patients, 
whose colonoscopy and biopsy results not confirmed IBDs 
were selected as controls.  
Both groups were interviewed and if they had previous 
records of IBDs, former treatments for eradication of H. 
pylori, history of taking proton pump inhibitors, receiving 
sulfasalazine or type-2 histamine receptor blockers, 
antiretroviral drugs, taking any drugs affecting intestines, 
and any diagnosed concurrent intestinal infections, were 
excluded from the study. 
The study data included demographics (age, gender, 
place of residence, weight, height, and educational 
attainment) and clinical information (records of taking 
proton pump inhibitors and sulfasalazine, eradication of 
helicobacter pylori, receiving type-2 histamine receptor 
blockers, antiretroviral drugs, and previous IBDs). To check 
the presence of helicobacter pylori exposure, 1 cc of venous 
blood was taken from all patients. Then an ELISA kit (made 
by Padtan Elm Co. with cutoff range of <20AU/ml negative, 
20-30AU/ml equivocal and >30AU/ml positive) was used to 
measure the titrations of serum IgA and IgG antibodies 
against H. pylori through indirect ELISA. The results were 
recorded on the checklist.  
Statistical analysis: We used SPSS software Version 18. 
The chi-square and t-test were applied in bivariate analysis 
for categorical and continuous data, respectively. Multiple 
logistic regression model performed to estimate adjusted 
odds ratio of H. pylori seropositivity and its 95% confidence 
interval by controlling sex and educational level. In variable 
selection, we used stepwise method. In logistic regression 
model, the independent variables were helicobacter 
seropositivity versus negative, female versus male and 
education level (low versus high) that were defined as 
indicator variables. The dependent variable was case status 
(case versus control).  The significance level was considered 
less than 0.05 for all cases. 
 
 
Results 
The demographic findings are stated in table.1. Thirty 
one (51.7%) cases and 90 (75%) controls had positive IgG 
for H.pylori (more than 30 AU/ml) (P=0.002). 28 (46.7%) 
cases and 62 (51.7%) controls had positive IgA for H.pylori 
(more than 30 AU/ml) (P=0.635) (table 1). 
There was a significant difference between cases and 
controls in H. pylori exposure based on IgG test in these 
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subgroups: age below 30 years old (P=0.004), females (men 
with P=0.047 and women with P=0.014), urban residency 
(P=0.002), academic education (P=0.013), BMI between 
18.5 and 24.9 (P=0.003). The female gender, lowest level of 
education (undergraduate) and positive results of IgG test for 
H.pylori were regarded as independent factors having 
protective roles in IBDs after moderating the intervener 
variables (P=0.002, 0.013, and 0.010) (table 2) 
 
Table 1. Demographic characteristics and serologic findings of patients with IBD and the control group 
Variable Group P-value 
Case Control 
Gender Male 41 (68.3%) 60 (50.0%) 0.007 
Female 19 (31.7%) 60 (50.0%) 
Age (year) ≤30 13 (21.7%) 12 (10.0%) 0.104 
30-50 32 (21.7%) 73(60.8%) 
>50 15 (25.0%) 35 (29.2%) 
Place of Residence Urban 32 (53.3%) 53 (44.2%) 0.270 
Rural 28 (46.7%) 67 (55.8%) 
Educational Attainment* Illiterate 5 (8.3%) 19 (18.4%) 0.026 
Primary  12 (20.0%) 7 (6.8%) 
High school 13 (21.7%) 30 (29.1%) 
Academic education 30 (50.0%) 47 (45.6%) 
BMI 
Kg/m2 
<18.5 10 (16.7%) 9 (7.5%) 0.165 
18.24-25.9 32 (53.3%) 61 (50.8%) 
25.9-29 16 (26.7%) 47 (39.2%) 
≥30 2 (3.3%) 3 (2.5%) 
IgG** Positive 31 (51.7%) 90 (75.0%) 0.002 
Negative 29 (48.3%) 30 (25.0%) 
IgA** Positive 28 (46.7%) 62 (51.7%) 0.635 
Negative 32 (53.3%) 58 (48.3%) 
*there were missing data from this item in control group. **<20AU/ml negative 20-30AU/ml Equivocal >30AU/ml positive 
 
Table 2. The adjusted odds ratio and its 95% confidence interval of associated factors with IBD risk using multiple logistic 
regression model with stepwise method 
 
Variable Odds ratio 95% CI* P-value 
Female versus male 0.33 0.16 ; 0.66 0.002 
Low versus high graduation level 6.24 1.48 ; 26.24 0.013 
Positive IgG versus negative IgG 0.39 0.19 ; 0.80 0.010 
                                                  CI: confidence interval 
 
Discussion 
The research findings indicate that exposure of H pylori 
has a protective role against IBDs. Many organisms are 
proposed as triggering factor in the pathogenesis of IBD but 
none of them have been proven. Gastrointestinal infections 
can make quick changes in the population of bacteria causing 
IBDs (2, 12, 13). In this regard, the role of H. pylori in 
ulcerative colitis has been investigated in many studies (2,  
14). El-Omar et al. reported the inverse relationship between  
 
H. pylori and IBD in 1994 for the first time. Then other 
studies attributed this relationship to the consumption of 
sulfasalazine. Nevertheless, different rates of prevalence 
were apparently independent of sulfasalazine. Another study 
indicated that the onset ages of IBD had nearly 10 years 
difference in patients with negative and positive H. pylori 
(15, 16). Ram et al. reported the relationship between H. 
pylori and IBDs (17). Nonetheless, Oliviera et al. and Parlak 
et al. did not find any relationship between H. pylori and 
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ulcerative colitis (18, 19). In this study, the ELISA method 
for detection of anti-helicobacter IgG and IgA was used to 
identify H. pylori exposure. IgA showed no significant 
difference between cases and controls. However, IgG 
detection showed 75% of controls and 51.7% of cases had 
prior exposure to H. pylori. This statistically significant 
difference indicates a lower rate of helicobacter pylori 
exposure in patients with IBD compared to the control 
group. According to Jin et al., the conditions of patients with 
UC got severed when H. pylori declined. This finding shows 
the negative relationship between H. pylori and ulcerative 
colitis. The possible hypothesis is the protective role of H. 
pylori against ulcerative colitis. Fewer UC patients were 
significantly reported to be affected by helicobacter pylori in 
comparison with the control group (2). Moreover, Jin et al. 
identified H. pylori infection through the urea breath test 
method a more acceptable method.  
Sladek et al. investigated 94 children who were newly 
diagnosed with IBD. The cases and controls were the same 
age and gender and in the same socioeconomic conditions. 
The results indicated that the rate of helicobacter pylori 
gastric colonization in child with IBD was significantly 
lower than the control group (9.6% compared with 38.4%). 
Helicobacter pylori gastric colonization was significantly 
higher in Crohn’s disease than in ulcerative colitis. There 
was no significant difference in the IBD average age of onset 
between positive and negative H. pylori groups. Finally, they 
stated that the prevalence of H. pylori was lower in IBD 
patients than in the control group, something which is not 
related to the eradication of helicobacter pylori because all 
the patients included in the study were newly-diagnosed, so 
they did not receive any treatments (20). 
Song et al. reported a significant difference between 
patients with IBD and the control group in H. pylori (25.3% 
in cases and 52.5% in controls). Furthermore, there was a 
significant difference between ulcerative colitis (32%) and 
Crohn’s disease (17.7%). In IBD patients younger than 60 
years old with the record of receiving metronidazole and 
ciprofloxacin, infection decreased significantly (13% and 
6.7%, respectively). Although, those who did not receive any 
antibiotics were affected by H. pylori less often than the 
control group (22% in Crohn’s disease, 33.8% in ulcerative 
colitis, and 52.5% in the control group). Apart from the age, 
other demographic variables did not show any effects on 
results. Finally, they stated that the prevalence of H. pylori in 
patients with IBD, especially Crohn’s disease, was lower 
than in the control group. This finding indicates that 
H. pylori infection supposed to decrease the possible risks of 
IBD in younger adults (21). 
Zhang et al. used PCR to investigate helicobacter pylori 
colonization in gastric tissue biopsies taken from patients 
with IBD. The results were not significantly different 
between IBD (10%) patients and the control (6.3%) group. 
In a cohort study conducted on 208 patients with IBD and 
416 controls, the urea breath test was carried out with carbon 
13. Significant results obtained from patients (19.7%) and 
control group (48.8%) in terms of H. pylori infection (22). 
According to the findings of this study, IBD was 
significantly related to gender and educational attainment. 
However, it was not significantly related to the effects of 
BMI, place of residence, and age. Though, Jin et al. reported 
a lower rate of BMI in IBD patients. 
Sonnenberg et al. conducted a pathology on 5493 
individuals (550 patients with IBD and 4943 controls 
without IBD) during endoscopy-colonoscopy procedures. 
They stated that Helicobacter-negative gastritis and 
duodenitis is more prevalent in patients with IBD than 
healthy controls (23). Roka et al. conducted a study in 2014 
and reported the prevalence of H. pylori in patients with IBD 
was significantly lower than the control group (3.8% to 
13.2%). IBD patients were significantly older than those 
patients without IBD. According to their study, the 
prevalence of helicobacter pylori in children with IBD was 
lower than in the control group. This study confirmed an 
inverse relationship between H. pylori and IBD (24). Vare et 
al. reported that the prevalence of H. pylori was lower in 
IBD patients than in the control group (24% to 37%). The 
onset age of IBD was lower in seronegative patients. Finally, 
they stated that the prevalence of H. pylori was lower in IBD 
patients particularly in Crohn’s disease. This finding shows 
the protective role of H. pylori (25). In Denmark, Bartels et 
al. studied H. pylori in patients with Crohn’s disease, 
ulcerative colitis, and celiac through the urea breath test in a 
6-year interval. They reported the low prevalence of Crohn’s 
disease in positive H. pylori cases compared with negative 
cases. They concluded that helicobacter pylori could play a 
protective role against Crohn’s disease (26). The possible 
explanations of these findings were proposed by many 
studies. A study suggested that H. pylori may prevent IBD 
by producing antibacterial peptide (27). Another study linked 
this role to IL-10 production in the mesenteric lymph nodes 
of the infected animals and to H. pylori DNA, which 
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contains a high ratio of immuneregulatory to 
immunostimulatory sequences. (28).  
In the present study, the results of the logistic regression 
analysis showed independent protective role of female 
gender, lower educational state and positive IgG for H.pylori 
against IBD. These findings are probably due to other 
aspects of their lifestyle which affects IBD occurrence. As it 
has been mentioned in recently published article “it could 
mean that H. pylori is merely an indicator of a lifestyle 
protective against Crohn’s disease rather than a causal 
factor” (9).  
The main limitation of the present study was the small 
sample size because it was focused on cases who were newly 
diagnosed with IBDs. To conquer the problem and achieve 
more power to defeat the effect size of interest, we increased 
the sample size of control in turn. Another limitation of this 
study was that the gold standard test for H. pylori diagnosis 
is tissue sampling and this problem can be solved with dual 
endoscopic study but this would cause additional burdens of 
an invasive procedure to the patients who are against medical 
ethics. The alternative method is urea breath test but 
unfortunately we did not access to this profit in our centers. 
According to the results, H. pylori exposure could play a 
protective role against IBDs. IBD is less frequently seen in 
females and in a population with lower level of education. 
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